


Surveillance of HIV DR in North America

Workshop
October 18-20

Forum for Collaborative
HIV Research

School of Public Health &
Health Services


The George Washington
University



The Forum for Collaborative HIV Research is a public/private partnership including government agencies, the pharmaceutical industry, HIV researchers and clinicians, and the HIV patient advocacy community.


Our mission is to facilitate and enhance HIV research.

The Forum Executive Committee



- Government Agencies
 - US DHHS (NIH, CDC, FDA, HRSA, CMS), State
 - European Regulatory: EMEA
- Industries
 - Abbott, Bayer Diagnostic, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Roche Laboratories, Roche Molecular Systems, Pfizer-Agouron, Tibotec, Virologic
- Academia
 - US and Europe
- Providers
- Patient Advocacy
 - US and Europe
- Foundations & Organizations (Gates, IAS)


Outcomes



- Reports and publications
- New research agendas
- New collaborations
- New funding mechanisms
- Increased level of engagement
- The “field has moved forward”

Surveillance of HIV DR in North America


October 18-20, 2004



- Special Acknowledgments
 - CDC
 - Health Canada
- Planning Committee Members
 - Chris Archibald
 - Diane Bennett
 - Walid Heneine
 - Susan Little
 - Veronica Miller
 - Eve Mokotoff

Surveillance of HIV DR in North America


October 18-20, 2004



- Very special thanks!
 - Ipsita Das, Project Coordinator
 - Houtan Mova

Surveillance of HIV DR in North America


October 18-20, 2004



- Is surveillance of HIV DR in North America important, necessary?
 - What are the public health actions and policy issues?
 - What information is needed for development of public health actions and policies?
 - Differentiate surveillance from “special studies”
- How is surveillance of HIV DR best integrated into current HIV surveillance systems?
- What are the best technological and logistic approaches?

Surveillance of HIV DR in North America


October 18-20, 2004



- Workshop format: Expert Discussion
- Agenda
 - Review of HIV and HIV DR Surveillance
 - Discussion of public health relevance and public health action
 - Specific issues in city, states & provinces
 - HIV DR in treated patients
 - Technology Issues
 - Database Issues
 - Recommendations

Surveillance of HIV DR in North America


October 18-20, 2004



- Introductions:
 - Diane Bennett (CDC)
 - Gayati Jayaraman (Health Canada)
 - Expert Panel
 - Regrets: Sally Blower; Scott Hammer

Policy & Public Health Actions


Comments contributed by Scott Hammer



- North America needs to be a partner if there is to be an effective Global Drug Resistance and Surveillance and Monitoring Program.
 - Need to be part of the international population sampling strategies for accurate accrual and dissemination of worldwide data
- Surveillance of sentinel drug naïve populations in North America will provide crucial national data concerning the prevalence of drug resistance over time. We lack a true picture of drug resistance in the US currently
 - Enable public health officials, policymakers, clinicians to recommend the appropriate use of drug resistance testing and the most efficient initial regimen

Policy & Public Health Actions

Comments contributed by Scott Hammer



- ARVs are typically introduced first in North America and Europe. Thus, well designed surveillance of drug naïve populations and monitoring of treatment experienced populations will provide data:
 - relevant for domestic decision making
 - will help to provide a global picture of the spread of DR as agents are introduced around the world
- Accurate drug resistance data at the population level can assist with the development and implementation of strategies to prevent its further spread